000 01543 a2200397 4500
005 20250516014303.0
264 0 _c20150629
008 201506s 0 0 eng d
022 _a1557-7465
024 7 _a10.1089/jir.2010.0074
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLotrich, Francis E
245 0 0 _aIL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy.
_h[electronic resource]
260 _bJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
_cMar 2011
300 _a331-6 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAdult
650 0 4 _aAntiviral Agents
_xadministration & dosage
650 0 4 _aFemale
650 0 4 _aGenotype
650 0 4 _aHepacivirus
650 0 4 _aHepatitis C
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aInterferon-alpha
_xadministration & dosage
650 0 4 _aInterferons
650 0 4 _aInterleukins
_xgenetics
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aPolymorphism, Single Nucleotide
700 1 _aLoftis, Jennifer M
700 1 _aFerrell, Robert E
700 1 _aRabinovitz, Mordechai
700 1 _aHauser, Peter
773 0 _tJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
_gvol. 31
_gno. 3
_gp. 331-6
856 4 0 _uhttps://doi.org/10.1089/jir.2010.0074
_zAvailable from publisher's website
999 _c20424906
_d20424906